Post by Cellbox Solutions

As global CGT development scales up, meeting GMP requirements becomes increasingly challenging. Ensuring an educated workforce, managing higher costs, and maintaining consistency across complex workflows are just a few examples. Yet one aspect that is still often underestimated in CGT manufacturing is logistics. Especially during final product testing, where processes are internationalized, companies face the challenge of maintaining consistency across multiple sites. Getting sensitive material from A to B depends on reliable logistical infrastructure. This is where warm-chain transport can play a crucial role, particularly for cells that are sensitive to freezing. Maintaining controlled conditions during transportation can help reduce the risk of cell loss, minimize handling complexity, and improve operational efficiency. Most importantly, it raises an important question: Does every site need to replicate the same GMP-intensive activities? In certain workflows, material arriving ready for immediate clinical use may help reduce the need to duplicate capabilities across multiple locations. How does your CGT workflow look? We'd love to hear about the challenges you're facing as therapies move toward broader clinical adoption. #CellAndGeneTherapy #WarmChainLogistics #Cellbox